Cargando…

Takotsubo cardiomyopathy and transient thyrotoxicosis during combination therapy with interferon-alpha and ribavirin for chronic hepatitis C

BACKGROUND: Thyroid dysfunction is a common complication of chronic hepatitis C (CHC) and its therapy. Takotsubo cardiomyopathy (TCM) is a multifactorial, stress related cardiomyopathy, rarely reported in association with thyrotoxicosis. Simultaneous occurrence of TCM and thyrotoxicosis due to hepat...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Carmen Sorina, Ionescu, Luminita Nicoleta, Barbu, Carmen Gabriela, Sirbu, Anca Elena, Lambrescu, Ioana Maria, Lacau, Ioana Smarandita, Dimulescu, Doina Ruxandra, Fica, Simona Vasilica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913789/
https://www.ncbi.nlm.nih.gov/pubmed/24491229
http://dx.doi.org/10.1186/1472-6823-14-10
_version_ 1782302289176821760
author Martin, Carmen Sorina
Ionescu, Luminita Nicoleta
Barbu, Carmen Gabriela
Sirbu, Anca Elena
Lambrescu, Ioana Maria
Lacau, Ioana Smarandita
Dimulescu, Doina Ruxandra
Fica, Simona Vasilica
author_facet Martin, Carmen Sorina
Ionescu, Luminita Nicoleta
Barbu, Carmen Gabriela
Sirbu, Anca Elena
Lambrescu, Ioana Maria
Lacau, Ioana Smarandita
Dimulescu, Doina Ruxandra
Fica, Simona Vasilica
author_sort Martin, Carmen Sorina
collection PubMed
description BACKGROUND: Thyroid dysfunction is a common complication of chronic hepatitis C (CHC) and its therapy. Takotsubo cardiomyopathy (TCM) is a multifactorial, stress related cardiomyopathy, rarely reported in association with thyrotoxicosis. Simultaneous occurrence of TCM and thyrotoxicosis due to hepatitis C and its treatment has never been reported. CASE PRESENTATION: A 47-year-old woman was admitted for acute chest pain, dyspnea, palpitations and diaphoresis. She had been diagnosed with CHC and had undergone 7 months of IFNα and Ribavirin therapy. At admission electrocardiogram (ECG) showed ST segment elevation, negative T waves and troponin was elevated suggesting ST segment elevation myocardial infarction (STEMI). Echocardiography demonstrated left ventricular apical akinesia and ballooning, with a left ventricular ejection fraction (LVEF) of 35%. Contrast angiography showed normal epicardial coronaries, yet a ventriculogram revealed left ventricular apical ballooning, consistent with TCM. Cardiac MRI showed left ventricle apical ballooning and no late enhancement suggesting the absence of any edema, scar or fibrosis in the left myocardium. She was diagnosed with non-autoimmune destructive thyroiditis: TSH=0.001 mU/L, free T4=2.41 ng/dl, total T3=199 ng/dl and negative thyroid antibodies. The thyroid ultrasonography showed a diffuse small goiter, no nodules and normal vascularization of the parenchyma. Following supportive treatment she experienced a complete recovery after a few weeks and she successfully completed her antiviral treatment, with no thyroid or cardiovascular dysfunction ever since. In patients treated with IFNα for CHC, the prevalence of thyroid dysfunction varies between 2.5–45.3% of cases. TCM is a stress related cardiomyopathy characterized by elevated cardiac enzymes, normal coronary angiography and an acute, transient, left ventricular apical dysfunction that mimics myocardial infarction. Most of the patients survive the initial acute event, typically recover normal ventricular function within one to four weeks and have a favorable outcome, as was the case with our patient. Thyrotoxicosis induced stress cardiomyopathy is rare and has been mostly reported in association with Graves’ disease, thyroid storm, thyrotoxicosis factitia or following radioiodine therapy for toxic multinodular goiter. CONCLUSION: Routine thyroid screening should be done in patients receiving IFN-alpha and Ribavirin for CHC and thyrotoxicosis should be considered as a possible and treatable underlying cause of TCM.
format Online
Article
Text
id pubmed-3913789
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39137892014-02-06 Takotsubo cardiomyopathy and transient thyrotoxicosis during combination therapy with interferon-alpha and ribavirin for chronic hepatitis C Martin, Carmen Sorina Ionescu, Luminita Nicoleta Barbu, Carmen Gabriela Sirbu, Anca Elena Lambrescu, Ioana Maria Lacau, Ioana Smarandita Dimulescu, Doina Ruxandra Fica, Simona Vasilica BMC Endocr Disord Case Report BACKGROUND: Thyroid dysfunction is a common complication of chronic hepatitis C (CHC) and its therapy. Takotsubo cardiomyopathy (TCM) is a multifactorial, stress related cardiomyopathy, rarely reported in association with thyrotoxicosis. Simultaneous occurrence of TCM and thyrotoxicosis due to hepatitis C and its treatment has never been reported. CASE PRESENTATION: A 47-year-old woman was admitted for acute chest pain, dyspnea, palpitations and diaphoresis. She had been diagnosed with CHC and had undergone 7 months of IFNα and Ribavirin therapy. At admission electrocardiogram (ECG) showed ST segment elevation, negative T waves and troponin was elevated suggesting ST segment elevation myocardial infarction (STEMI). Echocardiography demonstrated left ventricular apical akinesia and ballooning, with a left ventricular ejection fraction (LVEF) of 35%. Contrast angiography showed normal epicardial coronaries, yet a ventriculogram revealed left ventricular apical ballooning, consistent with TCM. Cardiac MRI showed left ventricle apical ballooning and no late enhancement suggesting the absence of any edema, scar or fibrosis in the left myocardium. She was diagnosed with non-autoimmune destructive thyroiditis: TSH=0.001 mU/L, free T4=2.41 ng/dl, total T3=199 ng/dl and negative thyroid antibodies. The thyroid ultrasonography showed a diffuse small goiter, no nodules and normal vascularization of the parenchyma. Following supportive treatment she experienced a complete recovery after a few weeks and she successfully completed her antiviral treatment, with no thyroid or cardiovascular dysfunction ever since. In patients treated with IFNα for CHC, the prevalence of thyroid dysfunction varies between 2.5–45.3% of cases. TCM is a stress related cardiomyopathy characterized by elevated cardiac enzymes, normal coronary angiography and an acute, transient, left ventricular apical dysfunction that mimics myocardial infarction. Most of the patients survive the initial acute event, typically recover normal ventricular function within one to four weeks and have a favorable outcome, as was the case with our patient. Thyrotoxicosis induced stress cardiomyopathy is rare and has been mostly reported in association with Graves’ disease, thyroid storm, thyrotoxicosis factitia or following radioiodine therapy for toxic multinodular goiter. CONCLUSION: Routine thyroid screening should be done in patients receiving IFN-alpha and Ribavirin for CHC and thyrotoxicosis should be considered as a possible and treatable underlying cause of TCM. BioMed Central 2014-02-03 /pmc/articles/PMC3913789/ /pubmed/24491229 http://dx.doi.org/10.1186/1472-6823-14-10 Text en Copyright © 2014 Martin et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Martin, Carmen Sorina
Ionescu, Luminita Nicoleta
Barbu, Carmen Gabriela
Sirbu, Anca Elena
Lambrescu, Ioana Maria
Lacau, Ioana Smarandita
Dimulescu, Doina Ruxandra
Fica, Simona Vasilica
Takotsubo cardiomyopathy and transient thyrotoxicosis during combination therapy with interferon-alpha and ribavirin for chronic hepatitis C
title Takotsubo cardiomyopathy and transient thyrotoxicosis during combination therapy with interferon-alpha and ribavirin for chronic hepatitis C
title_full Takotsubo cardiomyopathy and transient thyrotoxicosis during combination therapy with interferon-alpha and ribavirin for chronic hepatitis C
title_fullStr Takotsubo cardiomyopathy and transient thyrotoxicosis during combination therapy with interferon-alpha and ribavirin for chronic hepatitis C
title_full_unstemmed Takotsubo cardiomyopathy and transient thyrotoxicosis during combination therapy with interferon-alpha and ribavirin for chronic hepatitis C
title_short Takotsubo cardiomyopathy and transient thyrotoxicosis during combination therapy with interferon-alpha and ribavirin for chronic hepatitis C
title_sort takotsubo cardiomyopathy and transient thyrotoxicosis during combination therapy with interferon-alpha and ribavirin for chronic hepatitis c
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913789/
https://www.ncbi.nlm.nih.gov/pubmed/24491229
http://dx.doi.org/10.1186/1472-6823-14-10
work_keys_str_mv AT martincarmensorina takotsubocardiomyopathyandtransientthyrotoxicosisduringcombinationtherapywithinterferonalphaandribavirinforchronichepatitisc
AT ionesculuminitanicoleta takotsubocardiomyopathyandtransientthyrotoxicosisduringcombinationtherapywithinterferonalphaandribavirinforchronichepatitisc
AT barbucarmengabriela takotsubocardiomyopathyandtransientthyrotoxicosisduringcombinationtherapywithinterferonalphaandribavirinforchronichepatitisc
AT sirbuancaelena takotsubocardiomyopathyandtransientthyrotoxicosisduringcombinationtherapywithinterferonalphaandribavirinforchronichepatitisc
AT lambrescuioanamaria takotsubocardiomyopathyandtransientthyrotoxicosisduringcombinationtherapywithinterferonalphaandribavirinforchronichepatitisc
AT lacauioanasmarandita takotsubocardiomyopathyandtransientthyrotoxicosisduringcombinationtherapywithinterferonalphaandribavirinforchronichepatitisc
AT dimulescudoinaruxandra takotsubocardiomyopathyandtransientthyrotoxicosisduringcombinationtherapywithinterferonalphaandribavirinforchronichepatitisc
AT ficasimonavasilica takotsubocardiomyopathyandtransientthyrotoxicosisduringcombinationtherapywithinterferonalphaandribavirinforchronichepatitisc